E.g., 11/27/2024
E.g., 11/27/2024

BioFire Defense, a bioMérieux Company, Receives Prestigious Frost & Sullivan’s 2014 Global New Product Innovation Award for its FilmArray® Ebola Test

10 February, 2015

BioFire Defense, LLC is proud to announce that it is the recipient of the Frost & Sullivan’s 2014 Global New Product Innovation Award for its FilmArray® Ebola test. The New Product Innovation Award is given to companies that display strong overall performance in the development and market of an innovative new product, including adherence to U.S. Food and Drug Administration (FDA) criteria for Emergency Use Authorization (EUA)* and design of a product that addresses unmet needs.

bioMérieux’s business review for the year ended December 31, 2014

22 January, 2015

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2014.

bioMérieux and Astute Medical agreement to develop and market NEPHROCHECK® Test for VIDAS®

22 January, 2015

bioMérieux and Astute Medical sign a global agreement to develop and market NEPHROCHECK® Test for VIDAS®, an assay to assess the risk of developing acute kidney injury

Strategic alliance between bioMérieux and COPAN to automate clinical microbiology laboratories and enhance their operational efficiency

09 January, 2015

bioMérieux distributes COPAN’s WASP® and WASPLab™ automated systems and speeds up deployment of its “FMLA® - Lab Efficiency” vision.

bioMérieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections

10 December, 2014

bioMérieux, a world leader in the field of in vitro diagnostics, and Illumina, a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs.

bioMérieux Launches 3P™ Culture Media Range for Cleanrooms and Isolators

10 November, 2014

bioMérieux Industry, a bioMérieux unit dedicated to industrial application diagnostics, announces the launch of 3PTM, the new culture media product range specifically designed for cleanroom and isolator use. This advanced formulation was co-developed by a bioMérieux international research and development team and designed specifically for environmental monitoring in aseptic manufacturing environments.

BioFire Defense, a bioMérieux Company, Receives Fast-Track Authorization of  FilmArray® Ebola Test

27 October, 2014

BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its commercial FilmArray® Ebola test (BioThreat-E testTM).

Business Review for the Nine Months Ended September 30, 2014

22 October, 2014

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the nine months ended September 30, 2014.

bioMérieux's VITEK MS System Nominated for Prestigious 2014 U.S. Prix Galien Award

13 October, 2014

The First FDA-Cleared Diagnostic Instrument to Utilize MALDI-TOF Mass Spectrometry to Rapidly Identify Harmful Bacteria and Yeast Recognized by Galien Foundation for Innovation in Healthcare Science

bioMérieux Launches chromID® Salmonella Elite, the New Generation of Culture Media for Earlier Detection of Salmonella Strains in Clinical Fecal Samples

18 September, 2014

bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the launch of chromID® Salmonella Elite, a new selective chromogenic culture medium for the isolation and rapid identification of Salmonella in stool samples.

Pioneering Diagnostics